尼古丁胺胺单核酸作为治疗剂,以缓解败血症多器官衰竭的治疗作用
Ting Cao1, Rui Ni2,3, Weimin Ding4
1Institutes of Biology and Medical Sciences and Institute for Cardiovascular Science, Soochow University, Suzhou, 215123, China. caoting@suda.edu.cn.
Journal of translational medicine
|December 7, 2023
概括
尼古丁胺胺单核酸 (NMN) 提高了尼古丁胺腺氨酸二核酸 (NAD+) 水平,通过减少炎症和氧化应激来防止败血症引起的器官衰竭. 这项研究表明NMNN.
科学领域:
- 生物医学研究的研究.
- 细胞和分子生物学是细胞和分子生物学.
- 关键护理医学 关键护理医学
背景情况:
- 败血症引起的多器官衰竭是ICU中死亡的主要原因.
- 目前对败血症的治疗方法有限.
- 尼古丁胺胺单核酸 (NMN) 是NAD+的前体,显示出潜力,但需要进一步调查.
研究的目的:
- 为了研究NMN在败血症器官衰竭中的治疗作用.
- 阐明NMN在败血症中的作用的潜在机制.
主要方法:
- 在小鼠中通过结和刺穿诱导的败血症.
- 在NMN给药一小时后诱导败血症.
- 使用中性粒细胞,巨细胞和内皮细胞进行体外研究.
主要成果:
- 在败血症小鼠中,NMN的使用增加了NAD+水平,并减少了器官损伤,炎症和氧化应激.
- 通过减少细菌负担和ROS产生,NMN治疗降低了死亡率.
- 通过SIRT3信号传递,NMN增强了巨细胞和中性粒细胞的细胞和杀菌活性,同时减轻了内皮细胞功能障碍.
结论:
- 与NMN的NAD+补充提供了对败血症的保护.
- 通过SIRT3.3,NMN可以预防线粒体功能障碍,限制细菌的传播,并通过SIRT3.3减少炎症.
- 对于败血症治疗来说,NMN是一个潜在的治疗策略.
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Acute Respiratory Failure-V
142
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
142
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Role of Reduced Coenzymes NADH and FADH₂
11.7K
The energy released from the breakdown of the chemical bonds within nutrients can be stored either through the reduction of electron carriers or in the bonds of adenosine triphosphate (ATP). In living systems, a small class of compounds functions as mobile electron carriers, molecules that bind to and shuttle high-energy electrons between compounds in pathways. The principal electron carriers that will be considered originate from the B vitamin group and are derivatives of nucleotides; they are...
11.7K
Electron Transport Chain: Complex I and II
14.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.0K


